| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan (G.D.H.), Ann Arbor, Michigan 48109-0678; Department of Medicine, Division of Endocrinology and Metabolism (J.B.T.), and Department of Neurological Surgery (K.R.L., C.B.A., E.T.H, S.B., C.B.W.), University of California, San Francisco, California 94143; Department of Emergency Medicine, University of Texas Southwestern Medical Center (R.R.), Dallas, Texas 75390; and Department of Internal Medicine, Beth Israel Deaconess Medical Center (A.L.), Boston, Massachusetts 02215
Address all correspondence and requests for reprints to: Dr. Gary D. Hammer, Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan, 5560 MSRB-II, Box 0678, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0678. E-mail: ghammer{at}umich.edu.
Untreated Cushings disease and the resultant chronically elevated glucocorticoid levels lead to severe metabolic disturbances, including diabetes mellitus, obesity, hypertension, muscle wasting, and osteoporosis. Although transsphenoidal resection has become the standard of care for Cushings disease with high initial success rates, little information is available on the long-term morbidity and mortality of patients in remission compared with patients with recurrent or persistent Cushings disease after such treatment. We therefore conducted a retrospective study of 289 patients with Cushings disease who underwent transsphenoidal microsurgery for an ACTH-secreting adenoma at a tertiary care center exclusively by one surgeon (C.B.W.). Postoperative remission was achieved in 82% (n = 236) of patients, with best initial remission rates observed in patients with grade I (86%) and II (83%) or stage 0 (88%), A (94%), and B (100%) tumors. Male gender, larger tumor size, and higher stage predicted poorer initial outcome. Long-term follow-up was obtained on 178 patients, with a median follow-up time of 11.1 yr (range, 0.624.1 yr). Thirteen of 150 (9%) of patients in initial remission developed recurrent disease, and 12 patients underwent additional treatment. At last follow-up, only two of these patients had active disease. However, of the 28 patients with initial persistent disease who had follow-up greater than 6 months, 10 patients continued to have active disease at last follow-up. Although overall survival rates in patients with initial remission did not differ significantly from expected compared with the general population based on age and sex distribution, patients with initial persistent disease had a significant increase in mortality compared with the expected mortality. Thus, successful treatment of Cushings disease is associated with normal long-term survival. These results suggest that patients with persistent Cushings disease require early and aggressive intervention to attempt to prevent this excess mortality.
This article has been cited by other articles:
![]() |
B. M. K. Biller, A. B. Grossman, P. M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A. R. Hermus, L. J. Hofland, et al. Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2454 - 2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Petit, B. M. K. Biller, T. I. Yock, B. Swearingen, J. J. Coen, P. Chapman, M. Ancukiewicz, M. Bussiere, A. Klibanski, and J. S. Loeffler Proton Stereotactic Radiotherapy for Persistent Adrenocorticotropin-Producing Adenomas J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 393 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Patil, D. M. Prevedello, S. P. Lad, M. L. Vance, M. O. Thorner, L. Katznelson, and E. R. Laws Jr. Late Recurrences of Cushing's Disease after Initial Successful Transsphenoidal Surgery J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 358 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pouratian, D. M. Prevedello, J. Jagannathan, M. B. Lopes, M. L. Vance, and E. R. Laws Jr. Outcomes and Management of Patients with Cushing's Disease without Pathological Confirmation of Tumor Resection after Transsphenoidal Surgery J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3383 - 3388. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Dekkers, N. R. Biermasz, A. M. Pereira, F. Roelfsema, M. O. van Aken, J. H. C. Voormolen, and J. A. Romijn Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 976 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
R M Testa, N Albiger, G Occhi, F Sanguin, M Scanarini, S Berlucchi, M P Gardiman, C Carollo, F Mantero, and C Scaroni The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging Eur. J. Endocrinol., February 1, 2007; 156(2): 241 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Castinetti, M Nagai, H Dufour, J-M Kuhn, I Morange, P Jaquet, B Conte-Devolx, J Regis, and T Brue Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease Eur. J. Endocrinol., January 1, 2007; 156(1): 91 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Weil, A. O. Vortmeyer, L. K. Nieman, H. L. DeVroom, J. Wanebo, and E. H. Oldfield Surgical Remission of Pituitary Adenomas Confined to the Neurohypophysis in Cushing's Disease J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2656 - 2664. [Abstract] [Full Text] [PDF] |
||||
![]() |
R T Netea-Maier, E J van Lindert, M den Heijer, A van der Eerden, G F F M Pieters, C G J Sweep, J A Grotenhuis, and A R M M Hermus Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur. J. Endocrinol., May 1, 2006; 154(5): 675 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Taguchi, T Takao, Y Iwasaki, M Nishiyama, K Asaba, and K Hashimoto Suppressive effects of dehydroepiandrosterone and the nuclear factor-{kappa}B inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo J. Endocrinol., February 1, 2006; 188(2): 321 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Esposito, J. R. Dusick, P. Cohan, P. Moftakhar, D. McArthur, C. Wang, R. S. Swerdloff, and D. F. Kelly Early Morning Cortisol Levels as a Predictor of Remission After Transsphenoidal Surgery for Cushing's Disease J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 7 - 13. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |